Indian Vaccine Market to Grow at 12.3% During 2024-2032, Impelled by Rising Prevalence of Life-Threatening Diseases

September 22, 2017 | Healthcare

According to the latest report by IMARC Group, titled "Indian Vaccine Market Report by Monovalent and Combined Vaccines (BCG, HIB, Influenza, Varicella, Typhoid, Japanese Encephalitis, Measles, Tetanus Toxoid, Hepatitis A, Rubella, Diphtheria, Tetanus, and Pertussis (DPT), Oral Polio Vaccine (OPV), MMR, Rotavirus, Hepatitis B, Pneumococcal, Meningococcal, Rabies, HPV, Hexavalent, Dengue Vaccines) 2024-2032," the Indian vaccine market is expected to grow at a CAGR of 12.3% during 2024-2032. Vaccine refers to a medicine that aids in protecting against harmful diseases. It utilizes the body’s natural defenses in order to build resistance to infections while making the immune system stronger. It recognizes the invading foreign substance, such as the virus or bacteria, and produces antibodies that act as a barrier to prevent the infections. It is widely available in different forms, such as liquids, injection shots, nasal sprays and pills that defend the body against bacteria and viruses. Some of the commonly utilized vaccines include live-attenuated, inactivated, subunit, recombinant, polysaccharide, and conjugate, toxoid, messenger ribonucleic acid (mRNA) and viral vector vaccines.


Indian Vaccine Market Trends:

The Indian market is primarily driven by significant growth in the pharmaceutical industry. Along with this, the increasing investments by private and public firms for improving the overall pharmaceutical infrastructure is creating a positive market outlook. Moreover, the growing prevalence of life-threatening diseases, such as the rapid outbreak of coronavirus disease (COVID-19), has provided a boost to the demand for vaccines across the country. Additionally, numerous initiatives undertaken by the government of India to administer vaccines torural and underserved areas are impacting the market growth favorably. Furthermore, extensive research and development (R&D) activities conducted by key players for vaccine development, are supporting the Indian vaccine industry to grow significantly. The market is further driven by continual technological advancements in production processes and the advent of improved cold storage facilities.Other factors, including continuous improvements in the healthcare sector, the rising awareness among the masses, low cost of production, continual developments in the supply chain and distribution channels, and the increasing number of research laboratories and clinical centers, are also positively influencing the market across India.


Market Summary:

  • The market has been analyzed on the basis of various monovalent and combined vaccines into Bacillus Calmette–Guérin (BCG), Haemophilus influenzae type b (Hib), Influenza, Varicella, Typhoid, Japanese Encephalitis, Measles, Tetanus Toxoid, Hepatitis A, Rubella, Diphtheria, Tetanus and Pertussis (DPT), Oral Polio Vaccine (OPV), Measles, Mumps and Rubella (MMR), Rotavirus, Hepatitis B, Pneumococcal, Meningococcal, Rabies, Human Papillomavirus (HPV), Hexavalent and Dengue vaccines.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market. Some of these players include GlaxoSmithKline, Sanofi Aventis, Serum Institute of India, Panacea Biotec, Pfizer, Novartis, VHB Lifesciences, Zydus Cadila and MSD.


Report Scope:

Report Features Details
Base Year of the Analysis 2023
Historical Period 2018-2023
Forecast Period 2024-2032
Units Million, INR Million
Scope of the Report
Exploration of Historical and Forecast Trends, Industry Catalysts and Challenges, Segment-Wise Historical and Predictive Market Assessment:
  • Monovalent and Combined Vaccines
Monovalent and Combined Vaccines Covered BCG, HIB, Influenza, Varicella, Japanese Encephalitis, Measles, Tetanus Toxoid, Hepatitis A, Rubella, Diphtheria, Tetanus, and Pertussis (DPT), Oral Polio Vaccine (OPV), MMR, Rotavirus, Hepatitis B, Pneumococcal, Meningococcal, Rabies, HPV, Hexavalent, Dengue vaccines 
Companies Covered GlaxoSmithKline, Sanofi Aventis, Serum Institute of India, Panacea Biotec, Pfizer, Novartis, VHB Lifesciences, Zydus Cadila and MSD.
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2699
Five User License: US$ 3699
Corporate License: US$ 4699
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group

Tel: +1-631-791-1145
Email: sales@imarcgroup.com
Website: https://www.imarcgroup.com
Follow us on twitter: @imarcglobal

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Indian Vaccine Market to Grow at 12.3% During 2024-2032, Impelled by Rising Prevalence of Life-Threatening Diseases
Purchase Options
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials